Using Engineered Cardiac Fibroblasts to Repair Heart Tissue
Author Information
Author(s): Ruvinov Emil, Sharabani-Yosef Orna, Nagler Arnon, Einbinder Tom, Feinberg Micha S, Holbova Radka, Douvdevani Amos, Leor Jonathan
Primary Institution: Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel
Hypothesis
In situ expression of recombinant human erythropoietin (rhEPO) would improve tissue repair in rats after myocardial infarction (MI).
Conclusion
In situ expression of rhEPO enhances vascularization and reduces cell apoptosis in the infarcted myocardium, but does not improve heart function after MI in rats.
Supporting Evidence
- RhEPO-producing fibroblasts reduced apoptosis in cardiomyocytes exposed to oxidative stress.
- Transplanted rhEPO-producing fibroblasts enhanced vascularization in the infarcted myocardium.
- Local EPO therapy did not improve left ventricular function after myocardial infarction.
Takeaway
Scientists tried to help damaged hearts by using special cells that make a protein called EPO, which helps cells survive. They found that while the cells helped the heart heal a bit, they didn't make the heart work better.
Methodology
The study involved creating rhEPO-producing cardiac fibroblasts and transplanting them into rats after inducing myocardial infarction, followed by various assessments including echocardiography and histological analysis.
Potential Biases
Potential bias due to lack of quantification of cell engraftment and survival.
Limitations
Cell engraftment and survival were not quantified, and the study did not apply an immunosuppression protocol.
Participant Demographics
Male Sprague-Dawley rats, approximately 250 g.
Statistical Information
P-Value
p = 0.0006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website